Literature DB >> 26908750

Dengue Vaccine: The Need, the Challenges, and Progress.

Alan L Rothman1, Francis A Ennis2.   

Abstract

Keywords:  dengue; dengue vaccine; live virus vaccine; protective immunity; vaccine clinical trial

Mesh：

Substances：

Year:  2016        PMID： 26908750      PMCID： PMC4996144          DOI： 10.1093/infdis/jiw068

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  10 in total

1.  Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.

Authors:  Leah C Katzelnick; Magelda Montoya; Lionel Gresh; Angel Balmaseda; Eva Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

Review 2.  Trials and tribulations on the path to developing a dengue vaccine.

Authors:  Stephen J Thomas; Alan L Rothman
Journal:  Vaccine       Date:  2015-06-27       Impact factor: 3.641

3.  A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Marya P Carmolli; Cecilia M Tibery; Palmtama L Grier; Noreen Hynes; Kari Opert; Adrienne P Jarvis; Beulah P Sabundayo; Benjamin D McElvany; Eli A Sendra; Catherine J Larsson; Matthew Jo; Janece M Lovchik; Catherine J Luke; Mary C Walsh; Ellen A Fraser; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2016-02-16       Impact factor: 5.226

4.  Immunity to mumps in an institutional epidemic. Correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibiting antibodies.

Authors:  F A Ennis
Journal:  J Infect Dis       Date:  1969-06       Impact factor: 5.226

Review 5.  Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Alexander C Schmidt; Stephen S Whitehead
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

6.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Authors:  Sri Rezeki Hadinegoro; Jose Luis Arredondo-García; Maria Rosario Capeding; Carmen Deseda; Tawee Chotpitayasunondh; Reynaldo Dietze; H I Hj Muhammad Ismail; Humberto Reynales; Kriengsak Limkittikul; Doris Maribel Rivera-Medina; Huu Ngoc Tran; Alain Bouckenooghe; Danaya Chansinghakul; Margarita Cortés; Karen Fanouillere; Remi Forrat; Carina Frago; Sophia Gailhardou; Nicholas Jackson; Fernando Noriega; Eric Plennevaux; T Anh Wartel; Betzana Zambrano; Melanie Saville
Journal:  N Engl J Med       Date:  2015-07-27       Impact factor: 91.245

7.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

Authors:  Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

8.  Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination.

Authors:  R W Sutter; M A Pallansch; L A Sawyer; S L Cochi; S C Hadler
Journal:  Ann N Y Acad Sci       Date:  1995-05-31       Impact factor: 5.691

Review 9.  Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.

Authors:  Stefan Niewiesk
Journal:  Front Immunol       Date:  2014-09-16       Impact factor: 7.561

10.  The global distribution and burden of dengue.

Authors:  Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay
Journal:  Nature       Date:  2013-04-07       Impact factor: 49.962
  10 in total
  11 in total

Review 1.  Mapping the diverse structural landscape of the flavivirus antibody repertoire.

Authors:  Madhumati Sevvana; Richard J Kuhn
Journal:  Curr Opin Virol       Date:  2020-08-13       Impact factor: 7.090

2.  Discovery of host-targeted covalent inhibitors of dengue virus.

Authors:  Mélissanne de Wispelaere; Margot Carocci; Yanke Liang; Qingsong Liu; Eileen Sun; Michael L Vetter; Jinhua Wang; Nathanael S Gray; Priscilla L Yang
Journal:  Antiviral Res       Date:  2016-12-26       Impact factor: 5.970

3.  Oleic acid Enhances Dengue Virus But Not Dengue Virus-Like Particle Production from Mammalian Cells.

Authors:  Suwipa Ramphan; Sathiporn Suksathan; Nitwara Wikan; Puey Ounjai; Kanpong Boonthaworn; Poramate Rimthong; Tapanee Kanjanapruthipong; Suchin Worawichawong; Anan Jongkaewwattana; Nuttaporn Wongsiriroj; Duncan R Smith
Journal:  Mol Biotechnol       Date:  2017-10       Impact factor: 2.695

4.  Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus.

Authors:  Muhammad Tahir Ul Qamar; Arooma Maryam; Iqra Muneer; Feng Xing; Usman Ali Ashfaq; Faheem Ahmed Khan; Farooq Anwar; Mohammed H Geesi; Rana Rehan Khalid; Sadaf Abdul Rauf; Abdul Rauf Siddiqi
Journal:  Sci Rep       Date:  2019-02-05       Impact factor: 4.379

5.  The Clinical and Serological Profile of Pediatric Dengue.

Authors:  Sujatha Ramabhatta; Saravanan Palaniappan; Navya Hanumantharayappa; Shaik Vajidunnisa Begum
Journal:  Indian J Pediatr       Date:  2017-09-08       Impact factor: 1.967

Review 6.  The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design.

Authors:  Félix A Rey; Karin Stiasny; Marie-Christine Vaney; Mariano Dellarole; Franz X Heinz
Journal:  EMBO Rep       Date:  2017-12-27       Impact factor: 8.807

Review 7.  Peptides as Therapeutic Agents for Dengue Virus.

Authors:  Miaw-Fang Chew; Keat-Seong Poh; Chit-Laa Poh
Journal:  Int J Med Sci       Date:  2017-10-15       Impact factor: 3.738

8.  Assessing the interplay between human mobility and mosquito borne diseases in urban environments.

Authors:  Emanuele Massaro; Daniel Kondor; Carlo Ratti
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

9.  Validation of a Novel Zebrafish Model of Dengue Virus (DENV-3) Pathology Using the Pentaherbal Medicine Denguenil Vati.

Authors:  Acharya Balkrishna; Siva Kumar Solleti; Sudeep Verma; Anurag Varshney
Journal:  Biomolecules       Date:  2020-06-28

10.  Antibodies Against Modified NS1 Wing Domain Peptide Protect Against Dengue Virus Infection.

Authors:  Yen-Chung Lai; Yung-Chun Chuang; Ching-Chuan Liu; Tzong-Shiann Ho; Yee-Shin Lin; Robert Anderson; Trai-Ming Yeh
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.